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One-year prophylaxis with acyclovir has been shown to effectively prevent varicella-zoster virus (VZV)
reactivation after allogeneic hematopoietic stem cell transplantation (HSCT) in a cohort that underwent
transplantation in the beginning of the 2000s. Transplantation procedures have since changed consid-
erably and reduced-intensity conditioning (RIC) is nowadays common. We investigated VZV reactivation
without routine prophylaxis in a cohort of HSCT patients, 50% of whom had received RIC. The cumulative
2-year incidence of VZV reactivation was 20.7%. Risk factors in a multivariate analysis were treatment
with mesenchymal stromal cells (relative hazard [RH], 1.65; conﬁdence interval [CI], 1.07 to 2.54; P ¼ .02),
total body irradiation 6 Gy (RH, 1.55; CI, 1.14 to 2.13; P ¼ .006), engraftment later than day 16 (RH, 1.46;
CI, 1.07 to 2.00; P ¼ .02), and age 0 to 19 years (RH, 1.68; CI, 1.21 to 2.35; P ¼ .002). There was no dif-
ference in VZV reactivation between patients receiving myeloablative conditioning or RIC. VZV-related
complications occurred in 29% of the patients with reactivation; most common were disseminated dis-
ease and postherpetic neuralgia. No single low-risk group for VZV reactivation could be identiﬁed. We
conclude that VZV reactivation remains common after HSCT and carries a high complication rate, war-
ranting prophylaxis.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
The cumulative incidence of varicella-zoster virus (VZV)
reactivation (herpes zoster) after allogeneic hematopoietic
stem cell transplantation (HSCT) was reported to be around
50% during the 1990s, declining to a little over 20% in the
beginning of the 2000s [1-4]. Complications are common,
including postherpetic neuralgia, disseminated infection,
and occasional deaths [3,5-7]. One-year prophylaxis with
acyclovir or valacyclovir has been shown in a large cohort
study by Erard et al. to effectively prevent VZV reactivation
without evidence of rebound after discontinuation [1].
However, it is important to recognize that the control cohort
not given prophylaxis in the Erard study underwent trans-
plantation more than 10 years ago, between 1998 and 2002,
with only .6% of the patients receiving reduced-intensity
conditioning (RIC). The 1-year cumulative incidence of VZV
after RIC HSCT was reported to be lower than after myeloa-
blative HSCT, but it has varied considerably in different
studies, ranging from 10% to 27% [1,5,8]. The aim of this study
was to investigate the incidence of VZV reactivation in a
center performing 50% RIC HSCT and not using long-termedgments on page 1649.
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MATERIALS AND METHODS
Patient Population
All VZV-seropositive patients undergoing allogeneic HSCT at the Kar-
olinska University Hospital, Huddinge, between January 2000 and August
2012, were included. Patient characteristics are presented in Table 1. The
study was approved by the Research Ethics Committee of Karolinska
Institutet.
Conditioning
RIC was given to 414 patients and consisted of ﬂudarabine 30 mg/m2/
day for 3 to 6 days in combination with any of the following modalities: (1)
cyclophosphamide (Cy) 60 mg/kg/day for 2 days (n ¼ 83), (2) 2  3 Gy total
body irradiation (TBI) and Cy 60 mg/kg/day for 2 days (n ¼ 70), (3) 2 Gy TBI
(n ¼ 42), (4) treosulphan 14 g/m2 for 3 days (n ¼ 55), or (5) 4 mg/kg/day
busulfan orally for 2 days (n ¼ 164) [9-11]. Myeloablative conditioning
consisted of Cy 60 mg/kg/d for 2 days in combination with either (1) 10 Gy
single-fraction TBI (n ¼ 2), (2) 4  3 Gy fractionated TBI (þVP16 or
melphalan in 22) (n¼ 143), or (3) 4 mg/kg/day busulfan for 4 days (n¼ 230)
(þVP16 or melphalan in 19) [12]. Thirteen patients with severe aplastic
anemia and a sibling donor received Cy 50 mg/kg/day for 4 days. Antithy-
mocyte globulin was given to 541 patients and alemtuzumab to 36 patients
as part of the conditioning, with the last dose on the day before trans-
plantation [13].
Prophylaxis
Acyclovir prophylaxis, 400 mg 2 times daily, was only used in patients
who had an IgG antibody titer to herpes simplex virus of10,000, and it was
administered until the absolute neutrophil count was .5  109/L [14].
Monitoring for cytomegalovirus infection was performed by PCR for cyto-
megalovirus DNA. The PCRmethods varied during the study period [8]. Viral
loads at the predetermined cut-off levels were treated preemptively using
intravenous ganciclovir or oral valganciclovir [8,15]. Treatment duration in
most cases was until the PCR result became negative. If this therapy failed,
either because of lack of efﬁcacy or toxicity, the patients were switched to
Table 1
Patient Characteristics and Risk Factor Analyses
No VZV Infection
n ¼ 630
VZV Infection
n ¼ 172
Univariate (P Value) Multivariate (HR, 95% CI, P Value)
Age 44 (<1-71) 34 (<1-67) .004 1.68, 1.21-2.35, P ¼ .002
Sex (M/F) 368/262 112/60 .13
Malignancy 563 (89%) 148 (86%) .28
ALL or lymphoma 132 (21%) 48 (28%) .07
Nonmalignant disorder 67 (11%) 24 (14%) .28
Disease stage (early/late)* 291/287 (46/46%) 91/74 (53/45%) .32
Donor age 35 (0-72) 34 (0-70) .35
Donor
HLA-identical related 236 (37%) 58 (34%) .42
MUD 324 (51%) 88 (51%)
Mismatched (related/URD) 70 (11%) (9/61) 26 (15%) (0/26)
Conditioning
MAC/RIC 295/335 (47/53%) 93/79 (54/46%) .11
TBI-based (>6 Gy) 152 (24%) 62 (36%) .003 1.55, 1.14-2.13 P ¼ .006
Chemo-based 477 (76%) 110 (64%)
ATG 421 (67%) 120 (69%) .52
Alemtuzumab 24 (3.8%) 12 (7%) .12
NC dose,  108/kg 9.6 (.2-81) 8.3 (.2-42) .31
CD34 dose,  106/kg 7.1 (.01-68) 6.7 (.03-43) .47
Stem cell source (BM/PBSC/CB) 145/451/34 (23/72/5%) 58/106/8 (34/62/5%) .02
G-CSF 155 (25%) 40 (23%) .78
aGVHD
0 258 (41%) 71 (41%) .81
I 136 (22%) 36 (21%) .75
II 171 (27%) 55 (32%) .73
III-IV 65 (10%) 10 (6%)
cGVHD (yes/no)y 160/402 (25%) 31/134 (18%) .02
CMV ser MM 234 (37%) 57 (33%) .40
EBV ser MM 102 (16%) 29 (17%) .94
MSC 53 (8%) 24 (14%) <.05 1.65, 1.07-2.54, P ¼ .02
Days to ANC > .5 (mean) 17.0 18.3 <.01 1.46, 1.07-2.00, P ¼ .02
HR indicates hazard ratio; M, male; F, female; ALL, acute lymphoblastic leukemia; MUD, HLA-A, -B, and -DR matched unrelated donor; mismatch, HLA-A, -B, or
-DR allele or antigen mismatch; URD, unrelated donor; MAC, myeloablative conditioning; RIC, reduced conditioning; TBI, total body irradiation; ATG, antith-
ymocyte globulin; NC, nucleated cell; BM, bone marrow; PBSC, peripheral blood stem cell; CB, cord blood; G-CSF, granulocyte colonyestimulating factor;
aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; CMV, cytomegalovirus; ser MM, serological mismatch; EBV, Epstein-Barr
virus; ANC, absolute neutrophil count.
Absolute numbers or median and range are presented if not stated otherwise.
* Early includes ﬁrst complete remission/ﬁrst chronic phase and nonmalignancies; late includes beyond ﬁrst complete remission/ﬁrst chronic phase (patients
with solid tumor not included).
y Chronic GVHD occurring before VZV.
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tivation, 400 mg 2 times daily, was recommended in patients with acute
GVHD grade II or higher and/or chronic GVHD treated with
immunosuppression.Reactivation of VZV
Reactivation of VZV was based on clinical ﬁndings, in most cases
conﬁrmed by detection of VZV DNA in material from the vesicular lesions.
Disseminationwas deﬁned as involvement of more than 1 dermatome, if not
adjacent; otherwise, it was deﬁned as involvement of more than 2 derma-
tomes. Postherpetic neuralgia was deﬁned as pain persisting in the affected
dermatome for more than 30 days after onset of reactivation.Statistical Analysis
The incidence of VZV infection was calculated using an estimator of
cumulative incidence curves. Patients were censored at the time of death or
last follow-up. Predictive analyses were based on the proportional hazard
model for subdistribution of competing risk. Univariate and multivariate
analyses were then performed using Gray’s test and the proportional sub-
distribution hazard regression model of Fine and Gray [17]. A stepwise
backward procedure was used to construct a set of independent predictors.
All predictors with a P value below .10 were considered and sequentially
removed if the P value in the multiple models was above .05. All tests were
2-sided. The type I error rate was ﬁxed at .05 for factors potentially associ-
ated with time-to-event outcomes. Categorical parameters were compared
using chi-square test and continuous variables were compared using the
Mann-Whitney test. Analyses were performed using the cmprsk package
(developed by Gray, June 2001), Splus 6.2 software (Insightful, Seattle, WA),
and Statistica software (StatSoft, Tulsa, OK).RESULTS
Cumulative Incidence of Reactivation of VZV
The median follow-up time was 2.4 years (range, 8 to
4664 days), and 59 patients were lost to follow-up during the
ﬁrst year after HSCT (7.4% of all HSCTs). In all, 172 patients
(21.4%) reactivated VZV at a median of 175 days after HSCT
(range, 1 to 2198), resulting in a total cumulative incidence of
22.6% (Figure 1A). Most reactivations occurred during the
ﬁrst year, and the vast majority occurred within 2 years after
HSCT (20.7%) (Figure 1A). No breakthrough infection during
acyclovir prophylaxis could be identiﬁed. There was no sig-
niﬁcant difference in VZV reactivation rate per year during
the study period (Figure 1B). Patients with VZV reactivation
had the same overall mortality as patients with no reac-
tivation (data not shown).
Risk Factors for VZV Reactivation
Risk factors for VZV reactivation in a multivariate
regression analysis were receiving mesenchymal stromal
cells (MSCs) (relative hazard [RH], 1.65; 95% conﬁdence in-
terval [CI], 1.07 to 2.54; P ¼ .02), TBI  6 Gy as a part of
conditioning (RH, 1.55; 95% CI, 1.14 to 2.13; P ¼ .006),
engraftment later than day 16 (RH, 1.46; 95% CI, 1.07 to 2.00;
P ¼ .02), and age 0 to 19 years (RH, 1.68; 95% CI, 1.21 to 2.35;
P ¼ .002). The incidence in 10-year age intervals was 24% in
Figure 1. (A) Cumulative incidence of VZV reactivations. (B) Two-year inci-
dence rates of VZV reactivation.
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29 years, 24% in 30 to 39 years, 15% in 40 to 49 years, and 18%
in patients >49 years of age. To analyze the effect of chronic
GVHD, a day-100 landmark analysis was performed, which
showed no correlation between chronic GVHD and VZV
reactivation. Because MSCs are used for treatment of severe
steroid-resistant GVHD, and, thus, the results could be
biased, the risk factor analysis was recalculated omitting all
patients with GVHD grades III to IV. This did not change the
result signiﬁcantly (RH, 1.82; P ¼ .01). Treatment with
placenta-derivedmesenchymal stem cells is evaluated in our
institution as an alternative to MSCs. The cumulative inci-
dence of VZV reactivation in patients receiving placenta-
derived mesenchymal stem cells was 17%, but there were
too few patients (n ¼ 19) to allow a multivariate analysis.
Also, the follow-up period for these patients was shorter (in
most cases between 1 and 2 years) than for patients treated
with MSCs. No difference in reactivation was seen when
comparing myeloablative and nonmyeloablative condition-
ing; total cumulative incidence was 22.1% and 18.9%,
respectively (chi-square test P ¼ .22).Complications
One death occurred in a patient with severe GVHD and
disseminated VZV reactivation. Out of 172 patients with VZV
reactivation, 50 patients (29%) developed 60 complications,
including 24 cases of disseminated VZV reactivation and 25cases of postherpetic neuralgia. Other complications were
eye involvement (5 patients), encephalitis (2 patients),
visceral zoster (2 patients), meningitis (1 patient), and facial
palsy (1 patient).
DISCUSSION
We found a cumulative 2-year incidence of VZV reac-
tivation of 20.7% in 802 seropositive patients undergoing
HSCT from 2000 to 2012, including 51.7% RIC trans-
plantations. This is somewhat lower than the 24.9% found in
the control group in the prophylaxis study by Erard et al. [1].
Unfortunately, data regarding administration of acyclovir
prophylaxis in the present study were unreliable, but the
most probable explanation is that acyclovir prophylaxis was
given to the many of the patients with GVHD (in accordance
with the guidelines during the study period), reducing the
incidence of reactivation in this high-risk group. This is
supported by the fact that the risk factor analysis showed no
correlation between GVHD and reactivation of VZV. Other
possible explanations include the retrospective design and
the fact that some of the patients were, after the ﬁrst
3 months, partly followed up in their home hospital. All VZV
reactivations occurring during this period might not have
been reported to the treating physician, and, thus, were not
documented.
In a multivariate analysis, factors signiﬁcantly associated
to reactivation of VZV were treatment with MSCs, TBI  6 Gy
as a part of conditioning, engraftment later than day 16, and
age between 0 and 19 years. Treatment with MSCs was
signiﬁcantly associated with reactivation of VZV also when
omitting patients with GVHD grades III to IV. The indication
for MSCs in patients without severe GVHD was mostly graft
support, and the ﬁnding indicates that it is the MSCs that
constitute the risk. This is not surprising, as MSCs are
powerful immune-modulating cells and known risk factors
for other infections after HSCT [18,19]. Reactivation of VZV
when using TBI has been reported previously, both in clinical
use in humans and in an experimental model in monkeys,
but the mechanism is not clear [1,3,18,20]. In the present
study, children between 10 and 19 years of age had the
highest incidence of VZV reactivation, 40%. Age 20 years or
older was protective in multivariate analysis. The incidence
of reactivation in children 0 to 9 years was 23%, giving a total
incidence of 31% in patients between 0 and 19 years of age. A
similar result was recently reported in a pediatric study, with
a 1-year incidence of VZV reactivation of 25%, and the
median age for children with VZV reactivation was signiﬁ-
cantly higher (11 years) than for those with no reactivation
(8 years) [21].
Importantly, none of the signiﬁcant risk factors had a risk
hazard over 2, and the cumulative incidence of VZV reac-
tivation in patients with none of the signiﬁcant risk factors
was as high as 13% (data not shown). This means that in the
present study no low-risk group not potentially beneﬁtting
from VZV prophylaxis could be identiﬁed. Complications,
such as disseminated VZV and postherpetic neuralgia, were
common, and a signiﬁcant proportion of the patients had
symptoms that were difﬁcult to treat, which is in accordance
with earlier reports [3,5,7]. The reason for not routinely using
VZV prophylaxis in our center was the ﬁnding that herpes
simplex virus infection after HSCT reduced relapse in pa-
tients with acute lymphoblastic leukemia [22]. This gener-
ated the hypothesis that VZV reactivation could have an
antileukemic effect, but no evidence of this could be seen in
the present study (data not shown). However, during the
O. Blennow et al. / Biol Blood Marrow Transplant 20 (2014) 1641e1665 1649study period, patients with acute or chronic GVHD routinely
received prophylaxis, which could explain why we found no
correlation between VZV reactivation and chronic GVHD.
To conclude, in this retrospective study in a single center
not using routine VZV prophylaxis, we found a 2-year inci-
dence of VZV reactivation after HSCT of 20.7%. There was no
signiﬁcant difference in incidence between patients
receiving myeloablative and RIC HSCT and a low-risk patient
group possibly not beneﬁtting from prophylaxis could not be
identiﬁed by multivariate risk factor analysis. Complications
to VZV reactivation were common. As a result, all HSCT pa-
tients at our center will receive VZV prophylaxis for at least
1 year or longer, if still on immunosuppressive treatment
because of GVHD.
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